Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Nyiregyhaza – page 14

164 clinical trials in Nyiregyhaza, Hungary across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Nyiregyhaza at a glance
164
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

164 trials in Nyiregyhaza

Open in trial search

Colitis ulcerative+2

Not recruiting

Study on Long-term Safety of Ustekinumab for Children with Crohn's Disease, Juvenile Psoriatic Arthritis, or Ulcerative Colitis

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Ustekinumab
  • Sponsor:Janssen Cilag International

Study on Vericiguat for Adults with Chronic Heart Failure with Reduced Ejection Fraction

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Vericiguat
  • Sponsor:Merck Sharp & Dohme LLC
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Novartis Pharma AG

Study Comparing Darolutamide and Androgen Deprivation Therapy to Placebo and Androgen Deprivation Therapy in Men with High-Risk Prostate Cancer Recurrence

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Bayer AG

Colitis ulcerative

Not recruiting

Study on Ustekinumab for Children with Moderate to Severe Ulcerative Colitis

Registered drug
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Ustekinumab
  • Sponsor:Janssen Cilag International

Crohn's disease

Not recruiting

Study on Ustekinumab for Children with Moderate to Severe Crohn's Disease

Registered drug
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Ustekinumab
  • Sponsor:Janssen Cilag International

Cardiovascular disorder+1

Not recruiting

Study on the Effects of Retatrutide for Patients with Severe Obesity and Cardiovascular Disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Cardiac failure+4

Not recruiting

Study on the Effects of CDR132L in Patients with Reduced Heart Function After a Heart Attack

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:CDR132L
  • Sponsor:Cardior Pharmaceuticals GmbH

Other cities in Hungary

The busiest research cities in the country

All 71 cities in Hungary

Clinical research in Nyiregyhaza

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on breast cancer treatments, including studies for triple-negative and HR-positive/HER2-negative variants. Research extends to bladder cancer and lymphoma treatments.

  • Advanced metastatic breast cancer therapies
  • Large B-cell lymphoma treatments
  • Bladder cancer immunotherapy combinations

Several studies are evaluating novel drug combinations and comparing their efficacy to standard treatments.

02 Cardiovascular & Metabolic Diseases

Comprehensive research into heart failure prevention and treatment of cardiovascular disease. Studies include innovative approaches for managing chronic conditions.

  • Heart failure prevention strategies
  • Cardiovascular risk reduction
  • Chronic kidney disease management

Trials are investigating new therapeutic combinations to improve patient outcomes in cardiovascular conditions.

03 Respiratory & Inflammatory Conditions

Studies addressing chronic rhinosinusitis and respiratory infections, with particular focus on nasal polyps treatment and viral lung infections.

  • Nasal polyps treatment innovations
  • Respiratory syncytial virus prevention
  • Asthma management strategies

Research includes both preventive measures and therapeutic interventions for respiratory conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.